Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in Arthritis & Rheumatology [doi.org/10.1002/art.41731]. The Reducing Immunogenicity of Pegloticase (RECIPE) trial demonstrated that 86 percent of patients (19 of 22) receiving co-therapy of KRYSTEXXA with the immunomodulator mycophen

RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil

AbbVie

Bristol-Myers

Seagen

Vertex Pharmaceuticals

Horizon Therapeutics has a clear path to significant sales growth.

Does 2021's Best Biopharma to Work for Belong in Your Portfolio?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces new NMOSD data being presented at the American Academy of Neurology's 73rd Annual Meeting.

New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology's 73rd Annual Meeting

The stock price of Horizon Therapeutics PLC (NASDAQ: HZNP) increased by 8.67% today. This is why it happened.

HZNP Stock Price Increased 8.67%: Why It Happened

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics to resupply the market with TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) beginning in April.

Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April

DEERFIELD, Ill.--(BUSINESS WIRE)--Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and fair that allows Chicagoland-area middle and high school students to explore the connection between science and baseball as well as showcase their STEAM talents. Horizon is a biotechnology company that addresses critical needs for people impacted by rare, autoi

Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Is Horizon Therapeutics (HZNP) Down 8.1% Since Last Earnings Report?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (pegloticase injection) concomitantly used with methotrexate to treat people with chronic gout refractory to conventional therapy, also known as uncontrolled gout. The current recommended dosing of KRYSTEXXA for adult patients is 8 mg given as intravenous infusions every two weeks, with each dose inf

First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of UPLIZNA for the prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica) from the Japanese Ministry of Health, Labour and Welfare. MTPC has rights to the development and commercialization of UPLIZNA for NMOSD as well as other potential future indication

UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual global innovation challenge called The Horizon Prize focused on speeding diagnosis and care for people impacted by rare disease. Each year, The Horizon Prize will pose a unique challenge question to encourage innovators and entrepreneurs to try to solve a problem associated with the rare disease com

Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multiple opportunities to drive long-term growth and solidify our future as an innovation-driven biotech company,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “With its deep, mid-stage biologics pipeline, strong R&D team and on-market medicine UPLIZNA®, Viela is a str

Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked No. 1 on the Fortune Best Workplaces in Biopharma 2021 list. This is the fifth consecutive year Horizon has been named to the list and the company's second time ranking No. 1. "We are especially honored to be named the number one Best Workplace in Biopharma during a year of both unparalleled innovation in our industry and tremendous challenges,” said Tim Walbert, chairman, president and chief executive of

Horizon Therapeutics plc Named Number One Best Workplace in Biopharma

Generac Holdings

Inmode Ltd

SVB Financial Group

Williams-Sonoma

Those looking for growth stocks to watch are always trying to discover top stocks making bullish moves amid rising profit estimates. Here are some ideas.

Screen Of The Day: These Growth Stocks Make Bullish Moves Amid Soaring Profits

The shares of Horizon Therapeutics PLC  (NASDAQ:HZNP)  are down 3.4% at $91.29 at last check.

Biopharmaceutical Stock Could Be Headed Towards Fresh Highs

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March: Cowen and Company 41st Annual Health Care Conference (Virtual) Date: Tuesday, Mar. 2, 2021 Presentation Time: 1:30 p.m. ET The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event. About Horizon Horizon i

Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of a month-long virtual storytelling experience to elevate the diverse voices and faces of the rare disease community and benefit Make-A-Wish Mid-Atlantic and Make-A-Wish Canada. The #RAREis photobooth adds to a global commitment to helping grant the wishes of children with life-threatening rare diseases and provide moments of joy during a challenging time. Today, there are more than 7,000 known rare dis

Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish®

Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.

Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat

The biopharmaceutical company released its latest quarterly update.

Why Horizon Therapeutics Stock Jumped Today

Horizon Therapeutics' (HZNP) CEO Tim Walbert on Q4 2020 Results - Earnings Call Transcript

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 21.90% and 7.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Surpass Estimates

Horizon Therapeutics soundly beat fourth-quarter views after capping off what the company called a "breakthrough year" with the launch of a new drug and reaping the benefits of an acquisition. The post Horizon's 'Breakthrough Year' Ends With Fourth-Quarter Earnings Beat appeared first on Investor's Business Daily.

Horizon's 'Breakthrough Year' Ends With Fourth-Quarter Earnings Beat

Shares of Horizon Therapeutics (NASDAQ:HZNP) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 128.57% over the past year to $1.28, which beat the estimate of $1.05.

Recap: Horizon Therapeutics Q4 Earnings

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance

Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the NANOS Annual Meeting.

New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase

Alexion Pharma

Barrick Gold

RealPage

Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Barrick Gold Corp. (NYSE:GOLD), Thryv Holdings Inc. (NASDAQ:THRY), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and RealPage Inc. (NASDAQ:RP).

News for Horizon Pharma Stock (HZNP)